| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | SEK 22,4M | +40% |
| Total assets | SEK 49,3M | +51% |
| Equity | SEK 22,5M | +40% |
| Employees | 0 | — |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | −9 | — | −1 573 | — | −1 | — | — |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −9 | 0 | −1 573 | 0 | −1 | 0 | 0 |
| Net financials | — | 1 193 | 1 | 8 110 | 8 500 | 16 000 | 22 400 |
| Profit before tax | −9 | 1 193 | −1 184 | 8 210 | 8 500 | 16 000 | 22 400 |
| Tax | −0 | −0 | −0 | −105 | −0 | −0 | −0 |
| Net profit | −9 | 1 193 | −1 184 | 8 105 | 8 500 | 16 000 | 22 400 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Total assets | 50 | 10 928 | 10 928 | 14 274 | 16 654 | 32 654 | 49 336 |
| Equity | 41 | 1 234 | 50 | 8 155 | 8 550 | 16 050 | 22 450 |
| Long-term debt | 0 | 6 100 | 3 500 | 0 | 0 | 0 | 0 |
| Short-term debt | 9 | 3 594 | 7 378 | 6 119 | 8 104 | 16 604 | 26 886 |
| Total debt | 9 | 9 694 | 10 878 | 6 119 | 8 104 | 16 604 | 26 886 |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RN Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Långängen Pharma AB | Company | 100.0% | 100.0% | 0001 |
| Person | Role here | Other companies |
|---|---|---|
| Rolf Nicklas Kullberg | Chief Auditor | 0 companies |
| Said Richard Karroum | Board of Directors | 0 companies |
| Ulrika Elisabeth Marie Håkansson | Board of Directors | 0 companies |
| Francois Alexander Karroum | Deputy Board Member | 0 companies |
| Anders Leif Håkansson | Chairman | 0 companies |